Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$500K Buy
1,381
+118
+9% +$40.4K 0.04% 128
2026
Q1
$444K Sell
1,263
-10
-0.8% -$3.56K 0.04% 118
2025
Q4
$417K Sell
1,273
-14
-1% -$4.44K 0.03% 117
2025
Q3
$363K Hold
1,287
0.03% 126
2025
Q2
$359K Sell
1,287
-113
-8% -$32K 0.03% 123
2025
Q1
$436K Buy
1,400
+228
+19% +$67.3K 0.04% 120
2024
Q4
$305K Buy
1,172
+122
+12% +$36.2K 0.03% 126
2024
Q3
$338K Sell
1,050
-250
-19% -$81.8K 0.03% 114
2024
Q2
$406K Sell
1,300
-200
-13% -$58.8K 0.04% 101
2024
Q1
$426K Sell
1,500
-52
-3% -$15.2K 0.04% 95
2023
Q4
$447K Buy
+1,552
New +$423K 0.05% 92

Other funds holding AMGN

Nixon Peabody Trust's AMGN Position: Q2 2026 in Review

Nixon Peabody Trust increased its Amgen (AMGN) stake by 9.3% in Q2 2026, buying an estimated $40.4K and bringing the position to 1,381 shares worth $500K. The position accounts for 0.04% of the portfolio, ranked #128.

Nixon Peabody Trust first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 1,278 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Nixon Peabody Trust held 1,381 shares of Amgen worth $500K as of Q2 2026.
  • Nixon Peabody Trust bought 118 Amgen shares in Q2 2026, an estimated $40.4K.
  • Amgen made up 0.04% of Nixon Peabody Trust's portfolio in Q2 2026, its #128 holding.
  • Nixon Peabody Trust first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 1,278 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.